ier5l Antibody

What is IER5L and why is it significant in cancer research?

IER5L (Immediate Early Response 5 Like) is a member of the Immediate Early Response family of genes that regulate Protein Phosphatase 2A (PP2A) activity. This protein has emerged as a significant factor in cancer biology due to its upregulation in aggressive cancers and strong association with metastatic disease. IER5L is particularly noteworthy for its role in prostate cancer progression, where it supports tumor growth, dissemination, and metastasis through mechanisms involving DNA replication and monomeric G protein regulators .

Research has demonstrated that IER5L expression is upregulated in multiple cancer types beyond prostate cancer, including non-small cell lung cancer (NSCLC), and is associated with disease prognosis and progression . The widespread involvement of IER5L across various malignancies makes it a valuable target for cancer research.

How can I detect IER5L expression in tissue samples?

Multiple methodological approaches can be employed to detect IER5L expression:

Immunohistochemistry (IHC):

• Fixation: Standard formalin fixation and paraffin embedding

• Antibody incubation: Anti-IER5L antibody (e.g., Invitrogen, PA5-56287 at 1:300 dilution) overnight at 4°C

• Visualization: EnVision Plus System-HRP with diaminobenzidine (DAB) as substrate

• Counterstaining: Mayer's hematoxylin

• Assessment: Staining intensity can be scored as 3 (strong), 2 (moderate), 1 (weak), and 0 (negative)

qPCR Analysis:

• Extract RNA using standard protocols

• Perform reverse transcription to obtain cDNA

• Use appropriate IER5L-specific primers

• Normalize expression to housekeeping genes

• Validate results using melting curve analysis

RNA Sequencing:

• Can be performed at bulk tissue level or using single-cell RNA sequencing (scRNA-seq)

• Useful for correlating IER5L expression with other genes or pathways

• Enables comprehensive analysis of expression patterns across different cell types

How should I validate the specificity of an IER5L antibody?

Proper antibody validation is critical for obtaining reliable results:

• Western Blot Validation:

  • Confirm specific binding at expected molecular weight

  • Include positive control (cell line with known high IER5L expression)

  • Include negative control (cell line with low expression or knockdown)

• Immunocytochemistry:

  • Examine subcellular localization (IER5L typically shows nuclear distribution in cell lines like U251)

• Knockdown Controls:

  • Use siRNA or shRNA against IER5L

  • Confirm reduction in signal intensity correlates with reduced mRNA/protein levels

• Tissue Panel Testing:

  • Test antibody across multiple tissue types known to have varying levels of IER5L expression

  • Compare results with mRNA expression data for concordance

What are the primary applications of IER5L antibodies in cancer research?

IER5L antibodies are valuable tools in cancer research for:

• Diagnostic and Prognostic Assessment:

  • Evaluate IER5L expression in tumor samples for correlation with clinical outcomes

  • Research shows IER5L expression has promising discrimination value between tumor and non-malignant tissues (AUC = 0.830 for related IER family member)

• Mechanistic Studies:

  • Investigate protein-protein interactions involving IER5L

  • Study subcellular localization and trafficking

  • Examine post-translational modifications

• Therapeutic Target Validation:

  • Assess effects of targeting IER5L in preclinical models

  • Evaluate changes in downstream signaling pathways

  • Monitor changes in tumor cell behavior following IER5L modulation

What experimental conditions optimize IER5L antibody performance?

To achieve optimal results with IER5L antibodies:

• Tissue Fixation:

  • Use 10% neutral buffered formalin (24-48 hours)

  • Avoid overfixation which may mask epitopes

• Antigen Retrieval:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Optimize time and temperature based on your specific tissue type

• Blocking:

  • Use 3-5% BSA or 5-10% normal serum from the species of secondary antibody

  • Include 0.1-0.3% Triton X-100 for permeabilization in immunofluorescence

• Antibody Dilution:

  • Perform titration experiments to determine optimal concentration

  • Typical dilutions range from 1:100 to 1:500 for IHC applications

• Incubation Conditions:

  • Primary antibody: Overnight at 4°C

  • Secondary antibody: 1 hour at room temperature

  • Gentle agitation may improve staining uniformity

How does IER5L contribute to cancer progression at the molecular level?

IER5L influences cancer progression through multiple interconnected mechanisms:

• PP2A Regulation:

  • IER5L modulates Protein Phosphatase 2A (PP2A) activity

  • This affects numerous signaling pathways implicated in tumor development

  • Disruption of PP2A function can promote cellular transformation

• Transcriptomic Effects:

  • IER5L silencing alters expression of genes involved in:

    • DNA replication

    • Monomeric G protein regulation

    • Cell cycle progression

    • Migration and invasion pathways

• Signaling Pathway Involvement:

  • GSEA analysis indicates IER5L expression correlates with:

    • Cell cycle regulation

    • NOTCH signaling pathway

    • Oxidative phosphorylation

• Immune Modulation:

  • Higher IER5L expression correlates with increased regulatory T cells and neutrophils

  • Associates with elevated immune checkpoint molecules, suggesting potential influence on tumor immune microenvironment

What are optimal experimental approaches for studying IER5L function in cancer models?

A multi-faceted experimental approach is recommended:

• Loss-of-Function Studies:

  • siRNA or shRNA-mediated knockdown

  • CRISPR-Cas9 gene editing for complete knockout

  • Evaluate effects on:

    • Cell proliferation, migration, and invasion

    • Foci formation

    • In vivo tumor growth and metastasis

• In Vivo Models:

  • Zebrafish xenograft models for initial screening

  • Immunocompromised mouse models for more comprehensive analysis

  • Orthotopic implantation for physiologically relevant tumor microenvironment

• Mechanistic Investigations:

  • Combine transcriptomic (RNA-seq) and proteomic approaches

  • Pathway analysis to identify downstream effectors

  • Protein-protein interaction studies to identify binding partners

How can I analyze correlations between IER5L expression and immune cell infiltration?

To investigate IER5L's relationship with tumor immune microenvironment:

• Computational Approaches:

  • Apply single-sample Gene Set Enrichment Analysis (ssGSEA)

  • Use established immune cell signature genes

  • Employ Spearman correlation analysis to determine associations between IER5L and immune cell types

• Methodological Workflow:

  • Download RNA-seq data from public databases (TCGA, GEO)

  • Normalize expression values

  • Calculate immune cell enrichment scores using ssGSEA

  • Perform correlation analysis between IER5L expression and immune cell populations

  • Use Wilcoxon rank sum test to explore differences in immune cell invasion between high and low IER5L expression groups

• Validation Approaches:

  • Multiplex immunofluorescence staining

  • Flow cytometry of fresh tumor samples

  • Spatial transcriptomics for location-specific analysis

What considerations are important when designing experiments to study IER5L and PP2A interactions?

When investigating the regulatory relationship between IER5L and PP2A:

• Co-immunoprecipitation Protocols:

  • Use cell lysates from relevant cancer cell lines

  • Employ anti-IER5L antibody for pulldown

  • Probe for PP2A catalytic, structural, and regulatory subunits

  • Include appropriate controls (IgG, input, flow-through)

• PP2A Activity Assays:

  • Measure phosphatase activity using commercial kits

  • Compare activity in IER5L-silenced vs. control cells

  • Use okadaic acid as a positive control for PP2A inhibition

• Phosphoproteomic Analysis:

  • Compare phosphorylation profiles in IER5L-knockdown vs. control cells

  • Focus on known PP2A substrates

  • Validate findings with western blots using phospho-specific antibodies

• Structural Studies:

  • Investigate direct binding using purified recombinant proteins

  • Consider proximity ligation assays for detecting interactions in situ

How should I interpret conflicting IER5L expression data between transcriptomic and proteomic analyses?

When facing discrepancies between RNA and protein-level data:

• Technical Considerations:

  • Evaluate RNA quality metrics (RIN score, fragment distribution)

  • Assess protein extraction efficiency

  • Review antibody specificity validation

  • Consider batch effects and normalization methods

• Biological Explanations:

  • Post-transcriptional regulation (miRNAs, RNA binding proteins)

  • Post-translational modifications affecting protein stability

  • Protein compartmentalization affecting detection

  • Alternative splicing generating isoforms

• Resolution Approaches:

  • Increase biological and technical replicates

  • Use orthogonal detection methods

  • Perform time-course analyses to detect temporal discrepancies

  • Consider cell type-specific differences using single-cell approaches

What is the relationship between IER5L expression and tumor mutation burden?

The relationship between IER5L and tumor mutation burden (TMB) can be investigated through:

• Correlation Analysis:

  • Calculate TMB from whole-exome or targeted sequencing data

  • Perform Spearman rank correlation analysis between IER5L expression and TMB

  • Higher IER5L expression has been correlated with higher TMB in NSCLC

• Mechanistic Investigation:

  • Examine IER5L expression in relation to DNA repair pathway genes

  • Analyze mutation signatures associated with high vs. low IER5L expression

  • Investigate potential causative relationships through in vitro models

• Clinical Significance:

  • Evaluate whether IER5L expression and TMB together provide stronger prognostic information

  • Assess potential as a biomarker for immunotherapy response

How can I develop a nomogram incorporating IER5L expression for cancer prognosis?

To construct a clinically relevant nomogram:

• Statistical Approach:

  • Use the "rms" package in R language

  • Perform multivariate Cox regression analysis to identify independent prognostic factors

  • Include IER5L expression alongside established clinical parameters

• Validation Methods:

  • Internal validation using bootstrap resampling

  • External validation with independent cohorts

  • Generate calibration plots to assess concordance between predicted and actual survival probability

• Clinical Implementation Considerations:

  • Determine optimal cutoff values for IER5L expression

  • Assess performance metrics (C-index, AUC)

  • Compare with existing prognostic models

What methodologies are recommended for studying the upstream regulation of IER5L?

To investigate factors controlling IER5L expression:

• Transcription Factor Analysis:

  • Identify potential transcription factors using databases like Harmonizome and GRNdb

  • Validate binding using chromatin immunoprecipitation (ChIP)

  • Perform reporter assays with IER5L promoter constructs

• miRNA Regulation:

  • Construct regulatory networks involving miRNAs

  • An EGR1-hsa-miR-8075-IER5L network has been identified in NSCLC

  • Validate miRNA binding using luciferase reporter assays

• Epigenetic Regulation:

  • Analyze DNA methylation data of IER5L

  • Correlate methylation levels with mRNA expression using Spearman rank correlation

  • Perform treatment with demethylating agents to assess effects on expression

• Signaling Pathway Analysis:

  • Investigate how stress conditions and growth factors affect IER5L expression

  • Examine response to treatment with pathway inhibitors

  • Compare with regulation patterns of other IER family members (IER2, IER5)